Licensing Strategies Benchmarking Analysis of The Top 20 Pharmaceutical Companies

Introduction:

Licensing is playing an increasing role in the business model of pharmaceutical and biotechnology companies. In 2001, 16.4 per cent of sales from the top 20 pharmaceutical company sales were derived from in-licensed drugs, equating to over $38 billion. However, both pharmaceutical and biotechnology companies must improve the execution of licensing deals to reduce the current rate of attrition. 

Scope:

* Data on the large pharmaceutical companies that need to increase licensing activity from 2001 to 2007 to deliver double digit growth 

* In-depth analysis of the deal trends for technology and product licensing agreements made by the top 20 pharmaceutical companies from 2000 to 2002 

Report Highlights:

Target validation will become the key technology to in-license to 2007, replacing genomics as the most popular sector. Competition to partner with target validation companies will increase dramatically. Therefore, companies must move from traditional fee-for-service agreements towards collaborative partnerships to secure licensing deals. 

Despite high costs, accessing late stage products through licensing will continue to be the priority for pharmaceutical companies. Companies need to position themselves as the ‘partner of choice’ by offering co-promotion rights and ‘quid pro quo’ drugs that allow biotechnology companies to gain sales and marketing experience. 

Cancer and CNS products are the most competitive areas for licensing. To be successful in securing such deals, pharmaceutical companies must structure the financial aspects of the deal to account for the biotechnology company’s requirements, in addition to their own needs.  

Reasons to Purchase:

* Understand why licensing agreements are failing to deliver the desired results 

* Identify what types of licensing agreements are being made, and understand the drivers that will determine investment over the next five years 

* Improve your company’s strategic approach to licensing agreements by evaluating Datamonitor’s best practice recommendations 

Publisher: Datamonitor Market and Sales Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Market_and_Sales.html#a179